Outcomes of Intraocular Metastasis From Lung Cancer in the Era of Targeted Therapy: A Systematic Review and Pooled Analysis

Published:August 06, 2022DOI:



      Metastasis to intraocular structures is a serious problem in lung cancer. Due to its rarity, however, limited information is available regarding the outcomes of treatment and prognosis. Literature often suggests a poor prognosis. We review current literature on the outcomes of systemic therapy and prognostic factors.


      We conducted a systematic review of English literature published during 2009 to 2022 identified via Medline and Google Scholar search. Publications reporting on tumor response in the eyes or overall survival of patients with intraocular metastasis due to lung cancer were included. Pooled analysis of patients receiving systemic therapy was performed, utilizing individual-level patient data.


      A total of 79 publications contributed 92 patients into the analysis. Choroid was the most affected intraocular structure, in 82% of patients. Histology was small cell in 13% and non-small cell in 87%. Targeted therapy was utilized in 45% of patients. A pooled analysis demonstrated that the median overall survival was 27 months (95% CI: 21.8-32.2). Visual response among those with reported assessment showed that 92% of them had stable or improved vision while 8% experienced worsening of vision. Several factors including the year of treatment, age, targeted therapy, and radiation showed a significant association with survival. The strongest predictor of improved survival was the receipt of targeted therapy, with a hazard ratio of 0.31 (95% CI: 0.14-0.71), P = .005.


      For lung cancer patients with intraocular metastasis, systemic therapy can produce a favorable outcome. Particularly when a targeted therapy is feasible, long-term survival can be achieved.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kreusel KM
        • Bechrakis NE
        • Wiegel T
        • Krause L
        • Foerster MH.
        Incidence and clinical characteristics of symptomatic choroidal metastasis from lung cancer.
        Acta Ophthalmol. 2008; 86 (Aug): 515-519
        • Kreusel KM
        • Wiegel T
        • Stange M
        • Bornfeld N
        • Hinkelbein W
        • Foerster MH.
        Choroidal metastasis in disseminated lung cancer: frequency and risk factors.
        Am J Ophthalmol. 2002; 134 (Sep): 445-447
        • Qu Z
        • Liu J
        • Zhu L
        • Zhou Q.
        A comprehensive understanding of choroidal metastasis from lung cancer.
        Onco Targets Ther. 2021; 14 (Aug 12): 4451-4465
        • Konstantinidis L
        • Damato B.
        Intraocular metastases: a review.
        Asia Pac J Ophthalmol (Phila). 2017; 6 (Mar-Apr): 208-214
        • Asteriou C
        • Konstantinou D
        • Kleontas A
        • et al.
        Blurred vision due to choroidal metastasis as the first manifestation of lung cancer: a case report.
        World J Surg Oncol. 2010; 8 (Jan 8): 2
        • Riess JW
        • Nagpal S
        • Das M
        • Neal JW
        • Kim JW
        • Wakelee HA.
        A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.
        J Thorac Oncol. 2013; 8 (Feb): e17-e18
        • Shah SU
        • Mashayekhi A
        • Shields CL
        • et al.
        Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients.
        Ophthalmology. 2014; 121 (Jan): 352-357
        • Ettinger DS
        • Wood DE
        • Aggarwal C
        • et al.
        NCCN guidelines insights: non-small cell lung cancer, version 1.2020.
        J Natl Compr Canc Netw. 2019; 17 (Dec): 1464-1472
        • Page MJ
        • Moher D
        • Bossuyt PM
        • et al.
        PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews.
        BMJ. 2021; 372: n160
        • Bouchez C
        • Pluvy J
        • Soussi G
        • et al.
        Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors.
        BMC Cancer. 2020; 20 (Dec 3): 1186
        • Singh N
        • Kulkarni P
        • Aggarwal AN
        • et al.
        Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature.
        Medicine (Baltimore). 2012; 91 (Jul): 179-194
        • Shields CL
        • Welch RJ
        • Malik K
        • et al.
        Uveal metastasis: clinical features and survival outcome of 2214 tumors in 1111 patients based on primary tumor origin.
        Middle East Afr J Ophthalmol. 2018; 25 (Apr-Jun): 81-90
        • Rolfo C
        • Mack PC
        • Scagliotti GV
        • et al.
        Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC.
        J Thorac Oncol. 2018; 13 (Sep): 1248-1268
        • Vinores SA
        • Küchle M
        • Mahlow J
        • Chiu C
        • Green WR
        • Campochiaro PA.
        Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor.
        Am J Pathol. 1995; 147 (Nov): 1289-1297